XBiotech Inc. (NASDAQ:XBIT) recovered 326.76% of its value since hitting low of $2.13. The recent move of -5.41% drop pushed the stock to close at $9.09 when trading ended on 3/14/2019. At a recent session, the prices were hovering between $8.65 and $9.55. This company shares are 10.01% off its target price of $10 and the current market capitalization stands at $303.79M. The recent change has given its price a 21.85% lead over SMA 50 and -16.45% deficit over its 52-week high. The stock witnessed 8.21% gains, 110.42% gains and 293.51% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found XBIT’s volatility during a week at 10.06% and during a month it has been found around 9.04%.

XBiotech Inc. (XBIT) Top Holders

Institutional investors currently hold around $11 million or 13.2% in XBIT stock. Look at its top three institutional owners: Vanguard Group Inc owns $4.21 million in XBiotech Inc., which represents roughly 1.38% of the company’s market cap and approximately 38.23% of the institutional ownership. Similar statistics are true for the second largest owner, Geode Capital Management, Llc, which owns 135,163 shares of the stock are valued at $1.3 million. The third largest holder is Eam Investors, Llc, which currently holds $1.21 million worth of this stock and that ownership represents nearly 0.4% of its market capitalization.

XBiotech Inc. 13F Filings

At the end of December reporting period, 11 institutional holders increased their position in XBiotech Inc. (NASDAQ:XBIT) by some 204,646 shares, 11 decreased positions by 612,544 and 9 held positions by 301,559. That puts total institutional holdings at 1,118,749 shares, according to SEC filings. The stock grabbed 7 new institutional investments totaling 200,367 shares while 6 institutional investors sold out their entire positions totaling 87,728 shares.

XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.